SURMOUNT-1: Tirzepatide for Obesity The SURMOUNT-1 trial (NEJM, 2022) studied tirzepatide weight loss in 2,539 adults with obesity (without diabetes) over 72 weeks: STEP 1: Semaglutide for Obesity The STEP 1 trial (NEJM, 2021) studied semaglutide 2.4mg in 1,961 adults with obesity (without diabetes) over 68 weeks: Cross-Trial Summary Comparing across trials (with the caveat that indirect comparison has limitations): tirzepatide 15mg produced about 6 percentage points more weight loss than semaglutide 2.4mg over similar timeframes
A calorie deficit, the only way to lose weight, is when you burn more calories than you eat
Petanjek Z, Juda M, imic G, Rasin MR, Uylings HBM, Rakic P, et al
: , - , ,
Private hospitals and clinics are found throughout the region
A: Yes, CJC-1295 can be beneficial for women aiming to improve body composition, skin health, energy, and aging-related hormone decline